Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Kosel Medical Technology

Request full access

Specializes in coronary, peripheral intervention medical devices, electrophysiology products and others

ChinaHealth Tech & Medtech

About Kosel Medical Technology

Based in Suzhou, China, Kosel Medical Technology, also known as Kossel Medtech, was established in November 2013 by founder Navis Feng and CEO Arrow Hu, with an initial team of experts from both China and the USA. The company operates as a manufacturer and developer of endovascular medical devices for clinical treatments.

Kosel Medtech has structured its business into distinct platforms to address different areas of vascular intervention. The parent company focuses on peripheral intervention, its subsidiary Suzhou Haiyu Medtech provides solutions for tachycardia treatment, Mixin Medtech concentrates on coronary intervention products, and Haiwin Medtech is dedicated to the research and development of core raw materials. The company's business model includes the research, development, manufacturing, and distribution of its devices, and it also offers OEM/ODM cooperation for balloons and stents. Its products are sold to customers on every continent.

The firm's product portfolio is categorized into coronary, peripheral intervention, and electrophysiology. Key products include the PTCA Balloon Dilatation Catheter, Coronary Stent Systems, and Cardiac Ablation Catheters. One of its notable products is the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System, which features an ultra-thin strut and utilizes a proprietary supercritical fluid technology for drug coating. Another significant product is a vena cava filter, which was the first umbrella long-acting filter to be registered and commercialized in China. The company holds over 210 patents and intellectual property rights and has received CE, FDA, KFDA, and PMDA certifications.

Kosel Medtech has secured significant funding to support its growth and international expansion. The company raised over 100 million RMB in a Series B financing round in December 2023, led by Fortune Capital. This follows an earlier Series B round in January 2022 that raised $15.7 million. In total, the company has raised approximately $43.4 million from investors including Jushi Chuangtou, SND Private Equity Fund Management, Medpark, and Juming Venture Capital. A key milestone in its global strategy was the acquisition of Micell at the end of 2021.

Source: Dealroom company data

Kosel Medical Technology in its local ecosystem

Live from Dealroom

The Kosel Medical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Su Gaoxin Financial Holdings
  • Yuanhong Investment
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Kosel Medical Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Kosel Medical Technology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.